<DOC>
	<DOCNO>NCT02922192</DOCNO>
	<brief_summary>Purpose : With exist biologic anti-inflammatory product patent expire FDA approval new biosimilar innovator biologics , patient rheumatologic ( RA ) , psoriatic ( PsO-PsA-AS ) , gastrointestinal ( GI ) condition additional therapeutic option . This observational study describe patient characteristic new user Tumor Necrosis Factor-α ( TNF ) antagonists , non-TNF- α antagonist , oral DMARD , non-biologic agent . It describe treatment cohort outcomes serious infection require hospitalization . The BBCIC use finding descriptive analysis design comparative study evaluate real-world effectiveness safety biosimilar innovator anti-inflammatory biologics .</brief_summary>
	<brief_title>Incidence Hospitalizations Serious Infections Patients Receiving Biologic Anti-Inflammatories Rheumatologic , Psoriatic , Gastrointestinal Conditions : A Descriptive Analysis</brief_title>
	<detailed_description>Additional information : To effectively interpret result descriptive analysis important consider protocol design support hypothesis . This information provide public interest transparency demonstrate BBCIC 's Distributed Research Network 's ( DRN ) ability define exposure , outcome , covariates confounders . When publish , report caution protocol support ability compare safety effectiveness instead use explore feasibility future , detailed comparative analysis well understand capability BBCIC project . Further , report caution information protocol affect use medical product describe way fact BBCIC perform descriptive analysis way suggest safety effectiveness issue product describe .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Individuals baseline period 365 day continuous medical pharmacy coverage precede first prescription fill new user follow exposure TNF α antagonist ( include adalimumab , certolizumab , etanercept [ include IBD ] , golimumab , infliximab , natalizumab [ IBD ] ) NonTNFalpha antagonist biologics RA ( abatacept , rituximab , tocilizumab ) Nonbiologic medication ( use methotrexate previous year include RA : hydroxychloroquine , leflunomide , sulfasalazine ; IBD : 6 mercaptopurine azathioprine ; PsOPsAAS : methotrexate , leflunomide , sulfasalazine ) . During baseline 365 day , patient Active cancer history nonmelanoma cancer* Any immunocompromising condition ( organ transplantation , HIV , advance kidney/liver disease ) * *if occur followup period , patient also censor . During baseline 183 day , patient hospitalization infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Anti-inflammatory</keyword>
	<keyword>Biologics</keyword>
	<keyword>Biologic Biosimilars Collective Intelligence Consortium</keyword>
	<keyword>BBCIC</keyword>
</DOC>